Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus THORAZINE.
HALOPERIDOL LACTATE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol lactate is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways. It also has antagonistic activity at alpha-1 adrenergic receptors and limited affinity for serotonin receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
2-5 mg intramuscularly or intravenously every 4-8 hours for acute agitation. Maximum 20 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
14–26 hours (terminal elimination half-life); may be prolonged in hepatic impairment or with repeated dosing due to accumulation.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Renal (approximately 40% as metabolites, <1% as unchanged drug); fecal (approximately 15%); remainder metabolized with unknown fate.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic